38,460 results match your criteria patients hcc


Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway.

Phytomedicine 2021 Apr 18;87:153575. Epub 2021 Apr 18.

Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Electronic address:

Background: Hepatocellular carcinoma (HCC) is a common malignant tumor with limited treatment options. Conventional antitumor therapy combined with traditional Chinese medicine (TCM) to limit tumor progression has gradually become the focus of complementary and alternative therapies for HCC treatment. The Fuzheng Jiedu Xiaoji formulation (FZJDXJ) alleviates the clinical symptoms of patients and inhibits tumor progression, but its curative effect still requires extensive clinical research and mechanistic analysis. Read More

View Article and Full-Text PDF

Identification of SRGAP2 as a potential oncogene and a prognostic biomarker in hepatocellular carcinoma.

Life Sci 2021 May 10:119592. Epub 2021 May 10.

Department of Gastroenterology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China; Shaanxi Key Laboratory of Gastrointestinal Motility Disorders, Xi'an Jiaotong University, Xi'an, Shaanxi, China. Electronic address:

Background: Hepatocellular carcinoma (HCC) is one of the common malignancies worldwide. Slit-Robo GTPase-activating proteins (SRGAPs) have been shown to regulate the occurrence and development of various tumors. However, their specific roles in HCC remain elusive. Read More

View Article and Full-Text PDF

A Pre-TACE Radiomics Model to Predict HCC Progression and Recurrence in Liver Transplantation. A Pilot Study on a Novel Biomarker.

Transplantation 2021 Jan 7. Epub 2021 Jan 7.

1Multi-Organ Transplant Program, University Health Network, Toronto, Ontario, Canada 2Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Mount Sinai Hospital, Joseph & Wolf Lebovic Health Complex. Phone: + 1 (416) 586-8224. Ext 7804, Address: 600 University Avenue, 6th floor, office 6-200. M5G 1X5, Toronto, ON, Canada. 3Joint Department Medical Imaging, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada 4Genetics and Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario, Canada.

Background: Despite Trans-Arterial Chemo Embolization (TACE) for hepatocellular carcinoma (HCC), a significant number of patients will develop progression on the liver transplant (LT) waiting list or disease recurrence post-LT. We sought to evaluate the feasibility of a pre-TACE radiomic model, an imaging-based tool to predict these adverse outcomes.

Methods: We analyzed the pre-TACE computed tomography images of patients waiting for a LT. Read More

View Article and Full-Text PDF
January 2021

Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization.

Hepatol Res 2021 May 13. Epub 2021 May 13.

Division of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan.

We herein report two cases of locally advanced unresectable hepatocellular carcinoma (u-HCC) that were resected after achieving a radiological complete response to initially administered lenvatinib followed by transcatheter arterial chemoembolization (LEN-TACE sequential therapy). A 78-year-old woman and an 80-year-old man with HCC of Barcelona Clinic Liver Cancer classification stage C were treated for 15 and 14 months with lenvatinib, respectively. Both patients were subsequently treated with TACE, resulting in complete remission on imaging. Read More

View Article and Full-Text PDF

Development and Validation of a Novel Circulating miRNA-Based Diagnostic Score for Early Detection of Hepatocellular Carcinoma.

Dig Dis Sci 2021 May 12. Epub 2021 May 12.

Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation, Wuhan, Hubei, 430071, People's Republic of China.

Background: With the rise of liquid biopsy in oncology, circulating miRNAs have become one of the most promising noninvasive biomarkers for early detection of hepatocellular carcinoma (HCC). However, a reliable HCC-related circulating miRNA panel and corresponding diagnostic model remain to be explored.

Methods: Five large public datasets related to intact miRNA profiles in the serum or tumors of HCC patients were included and divided into training cohorts (GSE113740 and TCGA-LIHC) and validation cohorts (GSE112264, GSE113486 and GSE106817). Read More

View Article and Full-Text PDF

A Hepatocellular Carcinoma Patient with Mutations Benefits from Treatment with Everolimus: A Case Report.

Visc Med 2021 Mar 27;37(2):116-119. Epub 2020 May 27.

Liver Disease Center, Affiliated Hospital of Qingdao University, Qingdao, China.

Hepatocellular carcinoma (HCC) has a high degree of malignancy and poor prognosis. Treatment options for patients with advanced HCC are limited. There is currently no evidence to approve the accumulation of targeted therapies for HCC to support the inhibition of the PI3K/Akt/mTOR signaling pathway as an effective therapeutic strategy. Read More

View Article and Full-Text PDF

Predictors of 90-Day Mortality following Hepatic Resection for Hepatocellular Carcinoma.

Visc Med 2021 Mar 27;37(2):102-109. Epub 2020 Oct 27.

Hepato-Pancreatico-Biliary Surgery, Department of General Surgery, Tan Tock Seng Hospital, Singapore, Singapore.

Background/purpose: 90-day mortality is a key performance indicator for short-term perioperative outcome of hepatic resection (HR). Although many preoperative, intraoperative, and postoperative variables predict 90-day mortality following elective HR, only few are specific to hepatocellular carcinoma (HCC). This study aims to determine the predictors of 90-day mortality following elective HR for HCC. Read More

View Article and Full-Text PDF

Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort.

Visc Med 2021 Mar 7;37(2):87-93. Epub 2020 May 7.

I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Introduction: The number of efficacious systemic agents for advanced hepatocellular carcinoma (HCC) has rapidly increased over the past 3 years. However, guidance for optimal sequential systemic treatment in patients with advanced disease and experience with outcome and safety profiles are lacking.

Objective: We aimed to assess efficacy and tolerability of sequential systemic therapy of advanced HCC. Read More

View Article and Full-Text PDF

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma.

Front Mol Biosci 2021 26;8:615133. Epub 2021 Mar 26.

Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.

To identify the independent risk factors for transarterial embolization (TACE) refractoriness and to develop a novel TACE refractoriness score and nomogram for predicting TACE refractoriness in patients with hepatocellular carcinoma (HCC). Between March 2006 and March 2016, HCC patients who underwent TACE monotherapy as initial treatment at two hospitals formed the study cohort and validation cohort. The criteria of TACE refractoriness followed the Japan Society of Hepatology 2014 version of TACE refractoriness. Read More

View Article and Full-Text PDF

Trends and In-Hospital Outcomes of Splanchnic Vein Thrombosis Associated with Gastrointestinal Malignancies: A Nationwide Analysis.

Gastrointest Tumors 2021 Apr 9;8(2):71-80. Epub 2021 Feb 9.

Department of Oncology, Kansas University Medical Center, Kansas City, Kansas, USA.

Introduction: Gastrointestinal cancers have a strong association with splanchnic vein thrombosis (SVT), yet the hospitalization data is unknown.

Objective And Methods: We analyzed around 78 million discharges from the 2007-2017 Nationwide Inpatient Sample with an inclusion criterion of adult patients admitted for portal or hepatic vein thrombosis as a primary diagnosis with a gastrointestinal or hepatobiliary malignancy as a secondary diagnosis. The outcomes were in-hospital mortality, complication rates, and resource utilization. Read More

View Article and Full-Text PDF

Evolutionary Analysis of Pre-S/S Mutations in HBeAg-Negative Chronic Hepatitis B With HBsAg < 100 IU/ml.

Front Public Health 2021 26;9:633792. Epub 2021 Apr 26.

Clinical Medical Examination Center, Northern Jiangsu People's Hospital, Yangzhou, China.

Hepatitis B surface antigen (HBsAg) and viral load are important clinical indicators for antiviral therapy. Few studies have evaluated viral sequence biomarkers predicting the risk of hepatocellular carcinoma (HCC) in the stage, which show a low serological response (HBsAg < 100 IU/ml) and high viral levels (HBV DNA > 2,000 IU/ml). This study aims to determine the trend of the biological prevalence within the pre-S/S regions of special model of inactive CHB infection. Read More

View Article and Full-Text PDF

Texture Analysis Based on Gd-EOB-DTPA-Enhanced MRI for Identifying Vessels Encapsulating Tumor Clusters (VETC)-Positive Hepatocellular Carcinoma.

J Hepatocell Carcinoma 2021 5;8:349-359. Epub 2021 May 5.

Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215006, People's Republic of China.

Purpose: To determine the potential findings associated with vessels encapsulating tumor clusters (VETC)-positive hepatocellular carcinoma (HCC), with particular emphasis on texture analysis based on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI.

Methods: Eighty-one patients with VETC-negative HCC and 52 patients with VETC-positive HCC who underwent Gd-EOB-DTPA-enhanced MRI before curative partial hepatectomy were retrospectively evaluated in our institution. MRI texture analysis was performed on arterial phase (AP) and hepatobiliary phase (HBP) images. Read More

View Article and Full-Text PDF

MRI Features for Predicting Microvascular Invasion of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Liver Cancer 2021 Apr 11;10(2):94-106. Epub 2021 Mar 11.

Department of Radiology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea.

Purpose: Microvascular invasion (MVI) is an important prognostic factor in patients with hepatocellular carcinoma (HCC). However, the reported results of magnetic resonance imaging (MRI) features for predicting MVI of HCC are variable and conflicting. Therefore, this meta-analysis aimed to identify the significant MRI features for MVI of HCC and to determine their diagnostic value. Read More

View Article and Full-Text PDF

Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers.

Front Immunol 2021 26;12:642958. Epub 2021 Apr 26.

Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Representing the fourth leading cause of cancer-related mortality worldwide, liver cancers constitute a major global health concern. Hepatocellular carcinoma (HCC), the most frequent type of liver cancer, is associated with dismal survival outcomes and has traditionally had few treatment options available. In fact, up until 2017, treatment options for advanced HCC were restricted to broad acting tyrosine kinase inhibitors, including Sorafenib, which has been the standard of care for over a decade. Read More

View Article and Full-Text PDF

High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma.

Onco Targets Ther 2021 5;14:2975-2988. Epub 2021 May 5.

Graduate Department, Bengbu Medical College, Bengbu, Anhui, 233000, People's Republic of China.

Purpose: SLC41A3 is a member of the solute carrier family 41 (SLC41) and is involved in many cellular processes as a magnesium ion transporter. Although it plays an important role in cancer formation and development, the correlation between the expression of SLC41A3 and the occurrence and prognosis of hepatocellular carcinoma (HCC) remains unclear. Therefore, this study was focused on the evaluation of the relationship between SLC41A3 and the development and prognosis of HCC. Read More

View Article and Full-Text PDF

Eye movements in patients in early psychosis with and without a history of cannabis use.

NPJ Schizophr 2021 May 12;7(1):24. Epub 2021 May 12.

Institute of Psychiatry, Psychology and Neurosciences King's College London, London, UK.

It is unclear whether early psychosis in the context of cannabis use is different from psychosis without cannabis. We investigated this issue by examining whether abnormalities in oculomotor control differ between patients with psychosis with and without a history of cannabis use. We studied four groups: patients in the early phase of psychosis with a history of cannabis use (EPC; n = 28); patients in the early phase of psychosis without (EPNC; n = 25); controls with a history of cannabis use (HCC; n = 16); and controls without (HCNC; n = 22). Read More

View Article and Full-Text PDF

Is There a Difference Between LI-RADS 3 to LI-RADS 5 Progression Assessment Using CT Versus MR? A Retrospective, Single-Center, Longitudinal Study of Patients Who Underwent 5082 Radiologic Examinations for Surveillance of Hepatocellular Carcinoma Over a 43-Month Period.

Curr Probl Diagn Radiol 2021 Apr 14. Epub 2021 Apr 14.

Department of Radiology, University of Washington School of Medicine, Seattle, WA. Electronic address:

Objective: The Liver Imaging Reporting and Data System (LI-RADS) has been widely applied to CT and MR liver observations in patients at high-risk for hepatocellular carcinoma (HCC). We investigated the impact of CT vs MR in upgrading LI-RADS 3 to LI-RADS 5 observations using a large cohort of high-risk patients.

Methods: We performed a retrospective, longitudinal study of CT and MR radiographic reports (June 2013 - February 2017) with an assigned LI-RADS category. Read More

View Article and Full-Text PDF

Efficacy and safety of selective internal radiation therapy with yttrium-90 for the treatment of unresectable hepatocellular carcinoma.

BMC Gastroenterol 2021 May 12;21(1):216. Epub 2021 May 12.

Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul, 06273, Korea.

Background: This retrospective analysis was undertaken to evaluate the efficiency of SIRT with Y-90 microspheres and determined prognostic factors affecting patients with unresectable HCC.

Methods: A total of 97 patients diagnosed with unresectable HCC who underwent SIRT with Y-90 microspheres. Patient survival was assessed using the Kaplan-Meier method, and prognostic factors affecting survival were assessed using log-rank tests and Cox proportional hazards regression. Read More

View Article and Full-Text PDF

[Higher proportion of hepatitis B-related hepatocellular carcinoma combined with metabolic diseases in patients receiving antiviral therapy].

Zhonghua Gan Zang Bing Za Zhi 2021 Apr;29(4):344-349

State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.

To investigate the proportion of hepatitis B-related hepatocellular carcinoma (HCC) patients who have received antiviral therapy and compare the clinical characteristics of HCC patients who have received antiviral therapy with those who have not received antiviral therapy. Data of 2590 newly diagnosed hepatitis B-related HCC cases who were hospitalized in Nanfang Hospital from 2015 to 2017 were collected. Two independent sample t-tests, Mann-Whitney U test, and (2) test were used to compare the clinical characteristics of hepatitis B-related HCC patients who had received antiviral therapy and those who had not received antiviral therapy. Read More

View Article and Full-Text PDF

[Expression of tuftelin protein and its clinical value in HBV-related liver cancer tissues].

Zhonghua Gan Zang Bing Za Zhi 2021 Apr;29(4):338-343

Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China.

To analyze the expression of tuftelin protein (TUFT1) and its clinical value in hepatocellular carcinoma (HCC)-related liver cancer tissues. The biological information data of TUFT1 mRNA expression in liver cancer and non-cancer tissues were analyzed from the TCGA and Oncomine database. After the approval of the ethics committee, the self-pairing method was used to collect the postoperative cancer and para-carcinoma tissues of 132 HCC cases hospitalized between January 2009 and December 2014. Read More

View Article and Full-Text PDF

[Application of aMAP score to assess the risk of hepatocarciongenesis in population of chronic liver disease in primary hospitals].

Zhonghua Gan Zang Bing Za Zhi 2021 Apr;29(4):332-337

Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou 510515, China Shenzhen Hospital, Southern Medical University, Shenzhen 518110, China.

The aMAP score is a hepatocellular carcinoma (HCC) risk prediction model based on an international cooperative cohort, which can be applied to various liver diseases. The aim of this study is to use the aMAP score to stratify the risk of HCC in patients with chronic liver disease (combined or non-combined metabolic diseases) admitted to People's Hospital of Yudu County, Ganzhou City, Jiangxi Province, in order to guide personalized HCC screening. The demographic information, laboratory test results (platelets, albumin, and total bilirubin) and combined disease information of patients with chronic liver disease who were admitted to People's Hospital of Yudu from January 2016 to December 2020 were collected, and the aMAP score was calculated to stratify HCC risk in this population. Read More

View Article and Full-Text PDF

[Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].

Zhonghua Gan Zang Bing Za Zhi 2021 Apr;29(4):326-331

Department of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.

To analyze the clinical efficacy and safety of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma (HCC). Ninety-four cases with mid-and advanced-stage HCC who received camrelizumab combined with apatinib as second-line treatment were enrolled. Routine blood test, blood biochemical indexes, tumor stage, tumor imaging characteristics, previous treatment strategies and other clinical data before treatment were documented. Read More

View Article and Full-Text PDF

[Standardized screening and early imaging diagnosis strategies for hepatocellular carcinoma].

Authors:
X P Ren R K Li

Zhonghua Gan Zang Bing Za Zhi 2021 Apr;29(4):304-307

Departmen Affiliated to Medical College, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

Standardized hepatocellular carcinoma (HCC) screening is very important for early diagnosis. Chinese and international HCC clinical guidelines recommend regular ultrasound screening for high-risk patients. Noninvasive dynamic enhanced imaging technology should be selected for the positive screenin population to get the further diagnosis, including contrast-enhanced ultrasound (CEUS), dynamic contrast-enhanced CT, dynamic contrast-enhanced MRI and Gd-EOB-DTPA enhanced MRI (EOB MRI). Read More

View Article and Full-Text PDF

[Risk assessment and management of hepatocellular carcinoma occurrence in patients with chronic hepatitis B in the era of antiviral therapy].

Authors:
H G Xin Q Xie

Zhonghua Gan Zang Bing Za Zhi 2021 Apr;29(4):297-300

Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Chronic hepatitis B (CHB) virus infection remains the leading cause of hepatocellular carcinoma (HCC) in China. Oral antiviral drugs have been shown to significantly reduce the HCC risk in CHB patients, but it cannot completely eliminate the HCC occurrence. Therefore, accurate HCC risk assessment and standardized screening in CHB patients are essential for early diagnosis and improved prognosis. Read More

View Article and Full-Text PDF

[Oral nucleos(t)ide analogues antiviral therapy reduces HBV-related HCC: consensus and contention].

Authors:
C Han X G Dou

Zhonghua Gan Zang Bing Za Zhi 2021 Apr;29(4):293-296

Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang 110022, China.

Patients with chronic hepatitis B (CHB) who cannot receive effective antiviral therapy timely will eventually develop liver cirrhosis and/or hepatocellular carcinoma (HCC). Therefore, receiving nucleos(t)ide analogues (NAs) therapy can effectively inhibit hepatitis B virus (HBV) replication, improve liver tissue inflammation and fibrosis, prevent or delay the disease progression, and greatly reduce the occurrence of HBV-related HCC. However, it is often found in clinical practice that some patients treated with long-term NAs therapy can still develop HCC despite the effective inhibition of HBV replication. Read More

View Article and Full-Text PDF

Measuring quality of hepatitis B care in a remote Australian Aboriginal community; opportunities for improvement.

Intern Med J 2021 May 12. Epub 2021 May 12.

Hepatology and Liver Transplantation Medicine Unit, Flinders Medical Centre, Bedford Park, South Australia, Australia.

Background: Chronic hepatitis B (CHB) infection remains a significant public health issue for Indigenous Australians, in particular for remote communities.

Aim: This study aimed to evaluate the spectrum of hepatitis B virus (HBV) care provided to a remote Aboriginal community. Measures studied included screening, seroprevalence, vaccination rates and efficacy, and HCC risk and surveillance adherence. Read More

View Article and Full-Text PDF

CCL5-Deficiency Promotes HCC Progression by Affecting B-cell Recruitment.

J Dig Dis 2021 May 12. Epub 2021 May 12.

Department of Hepatic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Objectives: Abnormal expression of C-C chemokine motif ligand 5 (CCL5) occurs in many solid tumors. The mechanism by which CCL5 affects hepatocellular carcinoma (HCC) tumor progression is still unclear. Here, we aimed to evaluate the expression level of CCL5 in HCC, explore the function of CCL5 in regulating the immune microenvironment, and elaborate its regulatory mechanism involved in tumor immunity. Read More

View Article and Full-Text PDF

Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (HCC) with orbital metastases: a case report.

Ann Palliat Med 2021 May 11. Epub 2021 May 11.

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Sant'Orsola-Malpighi Hospital, Bologna, Italy.

Orbital metastases are an extremely rare finding in patients with hepatocarcinoma (HCC), especially as its first presentation. Therefore, the risk of misdiagnosis is high, as well as that of drastic delays of the therapeutic algorithm. Here we report a 71-year-old man presenting with orbital metastases as the initial sign of HCC, whose initial misdiagnosis led to the impossibility to start life-saving cancer treatment. Read More

View Article and Full-Text PDF

Trends in Indications and Outcomes of Liver Transplantation in Canada: A Multi Centre Retrospective Study.

Transpl Int 2021 May 11. Epub 2021 May 11.

Multi-Organ Transplant Program, University Health Network, Toronto, Ontario, Canada.

Background: The liver transplantation (LT) landscape is continuously evolving. We sought to evaluate trends in indications for LT in Canada and the impact of primary liver disease on post-LT outcomes using a national transplant registry.

Methods: Adult patients who underwent a primary LT between 2000 and 2018 were retrospectively identified in the Canadian Organ Replacement Registry. Read More

View Article and Full-Text PDF

and Expression in Hepatocellular Carcinoma and Tumor-Surrounding Liver Tissue.

Visc Med 2021 Mar 12;37(2):110-115. Epub 2021 Jan 12.

Department of Medicine II, Saarland University Medical Center, Homburg, Germany.

Introduction: The endoplasmic reticulum transmembrane proteins Sec61, Sec62, and Sec63 are responsible for the intracellular trafficking of precursor proteins and affect intracellular signaling. overexpression has been linked to various human cancers. Our aim was to investigate and expression in hepatocellular carcinoma (HCC) and surrounding liver tissue. Read More

View Article and Full-Text PDF